ArticleScience translational medicine2019
Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease.
Open access · bronzeAbstract read
In one paragraph
Article in Science translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 2 pooled it
7.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 2 syntheses or guidelines pooled it, 108 citations in OpenAlex.
- Role of bone marrow adipocytes in bone metastasis development and progression: a systematic review.Frontiers in endocrinology · 2023Pooled it
- Importance of circulating adipocytokines in multiple myeloma: a systematic review and meta-analysis based on case-control studies.BMC endocrine disorders · 2022Pooled it
- Bone Marrow Adipocytes in Multiple Myeloma: Emerging Immunometabolic Interactions and Implications for Immunotherapy.Cancers · 2026Review
- SEI1 complex silences p53 to drive myeloma progression.iScience · 2026Article
- Remodeling the marrow fat niche: BMAT in cancer bone metastases and hematological malignancies.Current opinion in endocrine and metabolic research · 2026Article
- Adipocyte-derived β-hydroxybutyrate confers metabolic resilience in multiple myeloma.Nature communications · 2026Article
- N-Acetylornithine Depletion in Bone Marrow Biopsy: A Novel Microenvironment-Specific Hallmark for Multiple Myeloma Diagnosis.International journal of laboratory hematology · 2026Article
- Effects of fatty acids and cholesterol on functions and behavior of bone marrow mesenchymal stem cells.iScience · 2026Review
- comBO: A combined human bone and lympho-myeloid bone marrow organoid for preclinical modeling of hematopoietic disorders.Cell stem cell · 2026Article
- Metabolism in Tumour-Induced Bone Disease.Current osteoporosis reports · 2026Review
- Metabolic reprogramming in tumor-associated cells of hematologic malignancies: mechanisms, crosstalk networks, and therapeutic implications in the tumor microenvironment.Frontiers in immunology · 2026Review
- Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a retrospective cohort study of electronic health records.EClinicalMedicine · 2026Article
- Darunavir analog precursors target mitochondrial metabolism in multiple myeloma and CLL.Cancer cell international · 2025Article
- Disruption of Marrow Microenvironments in Chronic Lymphocytic Leukemia by High-Resolution Synchrotron Micro-Computed Tomography.bioRxiv : the preprint server for biology · 2025Article
- LAMP5 modulates IRF4 stability and nuclear transport: a critical mechanism in myeloma progression and therapy.Oncogene · 2025Article
- Adipose Tissue-Derived Mediators in Multiple Myeloma: Linking Obesity to Bone Disease via Inflammatory Pathways.International journal of molecular sciences · 2025Review
- Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword.Cancer cell international · 2025Review
- Invasion and metastasis in cancer: molecular insights and therapeutic targets.Signal transduction and targeted therapy · 2025Review
- EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction.Nature communications · 2025Article
- Lipid metabolism in multiple myeloma: pathogenesis, therapeutic opportunities, and future directions.Frontiers in oncology · 2025Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
24 authors at 7 institutions in 2 countries.
Huan LiuDepartment of Lymphoma and Myeloma, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-5526-1417
Jin HeDepartment of Lymphoma and Myeloma, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Su Pin KohDepartment of Biochemistry and Molecular Biology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.ORCID 0000-0002-4410-6259
Yuping ZhongDepartment of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People's Republic of China.
Zhiqiang LiuDepartment of Lymphoma and Myeloma, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-0677-8097
Zhiqiang WangDepartment of Lymphoma and Myeloma, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Yujin ZhangDepartment of Lymphoma and Myeloma, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Zongwei LiDepartment of Lymphoma and Myeloma, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Bjorn T TamDepartment of Lymphoma and Myeloma, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-6740-8674
Pei LinDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Min XiaoDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-1551-6005
Ken H YoungDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Behrang AminiDepartment of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-4962-3466
Michael W StarbuckDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hans C LeeDepartment of Lymphoma and Myeloma, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Nora M NavoneDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-8645-6890
Richard E DavisDepartment of Lymphoma and Myeloma, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-7311-0065
Qiang TongUSDA/ARS Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.ORCID 0000-0003-1016-1839
P Leif BergsagelDivision of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA.ORCID 0000-0003-1523-7388
Jian HouDepartment of Hematology, Renji Hospital, Shanghai Jiaotong University School of Medicine, 160 Pujian Rd, Shanghai, People's Republic of China.
Qing YiCancer Center for Hematological Malignancies, Houston Methodist Hospital, Houston, TX 77030, USA.ORCID 0000-0003-1529-3398
Robert Z OrlowskiDepartment of Lymphoma and Myeloma, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Robert F GagelDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-9888-0362
Jing YangDepartment of Lymphoma and Myeloma, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. jiyang@mdanderson.org.ORCID 0000-0003-4235-7262
The University of Texas MD Anderson Cancer Center · USCapital Medical University · CNChildren's Nutrition Research Center at Baylor College of Medicine · USMayo Clinic in Arizona · USMethodist Hospital · USRenji Hospital · CNThe University of Texas Health Science Center at Houston · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MProject 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Rafael Fonseca · 2015 to 2026
$25.5MRole of integrin VLA-6 in suppression of bone formation in myelomaR01CA193362 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YANG, JING · 2016 to 2020
$1.8MTargeting adipocyte-secreted chemerin for chemotherapy resistance in myelomaR01CA190863 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YANG, JING · 2015 to 2019
$1.8MNCI NIH HHS P30 CA016672NCI NIH HHS P50 CA186781NCI NIH HHS R01 CA190863NCI NIH HHS R01 CA193362
Abstract
Osteolytic lesions in multiple myeloma are caused by osteoclast-mediated bone resorption and reduced bone formation. A unique feature of myeloma is a failure of bone healing after successful treatment. We observed adipocytes on trabecular bone near the resorbed area in successfully treated patients. Normal marrow adipocytes, when cocultured with myeloma cells, were reprogrammed and produced adipokines that activate osteoclastogenesis and suppress osteoblastogenesis. These adipocytes have reduced expression of peroxisome proliferator-activated receptor γ (PPARγ) mediated by recruitment of polycomb repressive complex 2 (PRC2), which modifies
Indexed as
Cellular ReprogrammingAdipocytesAdipokinesAnimalsBone DiseasesBone MarrowBone ResorptionCell Line, TumorDisease Models, AnimalDown-RegulationEnhancer of Zeste Homolog 2 ProteinHistonesHumansMethylationMiceMultiple MyelomaAdipokinesEnhancer of Zeste Homolog 2 ProteinHistonesPolycomb Repressive Complex 2PPAR gammaSp1 Transcription Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.